Herpes zoster vaccine (HZV): Utilization and coverage 2009 - 2013, Alberta, Canada

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Liu, Xianfang C ^a   Simmonds, Kimberley A ^b   Russell, Margaret L ^a   Svenson, Lawrence W ^a,b,c  

^a UNIVERSITY OF CALGARY   (Canada)

^b Epidemiology and Surveillance Team   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADULT; AGE; AGED; ALBERTA; FACTUAL DATABASE; FEMALE; HERPES ZOSTER; HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PHARMACY; STATISTICS AND NUMERICAL DATA; VACCINATION; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALBERTA; DATABASES, FACTUAL; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACIES; VACCINATION;

EID: 84928728927     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-1098     Document Type: Review

References (39)

1. World Health Organization: Immunization surveillance, assessment and monitoring. World Health Organization; 2014. [cited 214 Feb 4]. Available from http://www.who.int/immunization/monitoring-surveillance/en/.
2. Oxman MN: Zoster Vaccine: Current Status and Future Prospects. Clin Infect Dis 2010, 51:197-213.
3. Gershon AA, Takahashi M, Seward JF: Varicella vaccine. In Vaccines. 6th edition. Edited by Plotkin SA, Orenstein WA, Offit PA. Philadelphia, PA: Saunders; 2012:837-869.
4. National Advisory Committee on Immunization (NACI): Statement on recommended use of varicella virus vaccine. Can Commun Dis Rep 1999, 25:1-19.
5. Russell ML, Dover DC, Simmonds KA, Svenson LW: Shingles in Alberta: Before and after publicly funded varicella vaccination. Vaccine 2013, S0264-410X(13)01249-8. doi:10.1016/j.vaccine.2013.09.018. [Epub ahead of print].
6. Alberta Health: Childhood Coverage Rates-Varicella. Alberta Health. 2014. Government of Alberta. Aug 25, 2014.
7. Russell ML, Schopflocher DP, Svenson LW, Yiannakoulias N, Grimsrud K, Virani SN: The changing epidemiology of chickenpox in Alberta. Vaccine 2005, 23:5398-5403.
8. Russell ML, Schopflocher DP, Svenson L: Health disparities in chickenpox or shingles in Alberta? Can J Public Health 2007, 99:41-45.
9. Russell ML, Schopflocher DP, Svenson L, Virani SN: Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect 2007, 135:908-913.
10. National Advisory Committee on Immunization: Statement on the Recommended Use of Herpes Zoster Vaccine. Can Commun Dis Rep 2010, 36:1-19.
11. Shapiro M, Kvern B, Watson P, Guenther L, McElhaney J, McGeer A: Update on herpes zoster vaccination: A family practitioners guide. Can Fam Physician 2011, 57:1127-1131.
12. Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC): Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2008, 57:1-30.
13. Centers for Disease Control: Update on Herpes Zoster Vaccine: Licensure for Persons Aged 50 Through 59 Years. Morb Mortal Wkly Rep 2011, 60:1528.
14. Scheifele DW, Ward BJ, Halperin SA, McNeil SA, Crowcroft NS, Bjornson G: Approved but non-funded vaccines: accessing individual protection. Vaccine 2014, 32:766-770.
15. Government of Alberta. Health Information Act: Health Information Regulation (Alberta Regulation 70/2001 with amendments up to and including Alberta Regulation 49/2014). Alberta Regulation 70/2001, 2014. Health Information Act: Health Information Regulation.
16. Alberta Health: Alberta Netcare: EHR Usage Statistics 2013. [cited 2014 May 6] Available from http://www.albertanetcare.ca/Statistics.htm.
17. Hughes CA, Guirguis LM, Wong T, Ng K, Ing L, Fisher K: Influence of pharmacy practice on community pharmacists' integration of medication and lab value information from electronic health records. J Am Pharm Assoc 2011, 51:591-598.
18. Canada Post: Addressing Guidelines: Postal Code. 2014. [cited 2014 Mar 31] Available from http://www.canadapost.ca/tools/pg/manual/PGaddress-e.asp.
19. du Plessis V, Beshiri R, Bollman RD: Definitions of rural. Rural and Small-Town Canada Analysis Bulletin 2001, 3:1-17.
20. Martens PJ, Brownell M, Au W, MacWilliam L, Prior H, Schultz J, et al: Health Inequities in Manitoba: Is the Socioeconomic Gap Widening or Narrowing Over Time? Winnipeg, MB: Manitoba Centre for Health Policy; 2010. 4-28-2014.
21. Surveillance & Assessment Branch AH: Interactive Health Data Application: Demographics: Population Estimates, adjusted Alberta Health, 2013. Government of Alberta. March 13, 2013
22. Alberta Health and Wellness: Comparison of Alberta population counts between the AHCIP Registry and the 2006 census. Edmonton, AB: Government of Alberta; 2009:1-75.
23. Zou G: A Modified Poisson Regression Approach to Prospective Studies with Binary Data. Am J Epidemiol 2004, 159:702-706.
24. Canadian Medical Protective Association: New vaccines-what are your obligations? https://oplfrpd5.cmpa-acpm.ca/en/safety/-/asset-publisher/ N6oEDMrzRbCC/content/new-vaccines-what-are-your-obligations.
25. Sorensen M: Rural Alberta Profile: a fifteen year census analysis (1991-2006). 2010:1-89. 2-17-2014.
26. Alberta Health: Alberta Drug Benefit List.; 2014. [cited 2014 Apr 1] Available from http://www.health.alberta.ca/services/drug-benefit-list.html.
27. Hechter RC, Tartof SY, Jacobsen SJ, Smith N, Tseng HF: Trends and disparity in zoster vaccine uptake in a managed care population. Vaccine 2013, 31:4564-4568.
28. Canadian Immunization Committee: Summary of the CIC Recommendations for zoster immunization programs. Can Commun Dis Rep 2014, 40:170-171.
29. Law MR, Cheng L, Dhalla IA, Heard D, Morgan SG: The effect of cost on adherence to prescription medications in Canada. CMAJ 2012, 184:297-302.
30. Opstelten W, van Essen GA, Hak E: Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. Vaccine 2009, 27:192-196.
31. Joon Lee T, Hayes S, Cummings DM, Cao Q, Carpenter K, Heim L, Edwards H: Herpes Zoster Knowledge, Prevalence, and Vaccination Rate by Race. J Am Board Fam Med 2013, 26:45-51.
32. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA: The Incidence of Herpes Zoster in a United States Administrative Database. J Gen Intern Med 2005, 20:748-753.
33. Fleming DM, Cross KW, Cobb WA, Chapman RS: Gender Difference in the Incidence of Shingles. Epidemiol Infect 2004, 132:1-5.
34. Toyama N, Shiraki K, Society of the Miyazaki Prefecture Dermatologists: Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol 2009, 81:2053-2058.
35. Opstelten W, van Essen GA, Schellevis F, Verheij TJM, Moons KGM: Gender as an Independent Risk Factor for Herpes Zoster: A Population-Based Prospective Study. Ann Epidemiol 2006, 16:692-695.
36. National Advisory Committee on Immunization: Update on the use of herpes zoster vaccine; 2014. Cat.: HP40-92/2014E-PDF.
37. Turcotte M, Schellenberg G: A portrait of seniors in Canada 2006. 2007:1-301. [cited 2014 Aug 25]; 89-519-XIE:1-301. Available from http://publications.gc. ca/Collection/Statcan/89-519-X/89-519-XIE2006001.pdf.
38. Standing Senate Committee on Social Affairs SaT: Prescription pharmaceuticals in Canada: off label use; 2014:1-28. 3-31-2014.
39. Dalton B, Svenson L, Bresee L, Sabuda D, Missaghi B, Larios OE, Simmonds K, Conly J: External validation of estimates of antibacterial dispensing in the IMS Brogan Xponent® Database in a Canadian province; 2013. [cited 2014 Apr 28] Available from https://idsa.confex.com/idsa/2013/webprogram/Paper41244.html.